07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Potassium channel Kv7.3 (KCNQ3)

Neurology INDICATION: Depression Mouse studies suggest promoting KCNQ3 expression or opening potassium channels could help treat major depressive disorder (MDD). In a mouse model of chronic depression, expression of KCNQ3 in ventral tegmental area dopaminergic...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Company News

Meda, Valeant Pharmaceuticals sales and marketing update

This quarter, Meda and Valeant will terminate their joint commercialization ventures in Canada, Mexico and Australia. Meda said the companies can in the longer term "better explore opportunities" in the markets as separate entities. Valeant...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

Flupirtine-containing medicines regulatory update

EMA's Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) endorsed a recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC) to use oral flupirtine-containing medicines and suppositories only to treat acute pain in...
07:00 , May 17, 2010 |  BC Week In Review  |  Company News

Adeona, Meda deal

Adeona granted Meda exclusive rights to develop and commercialize flupirtine to treat fibromyalgia in the U.S., Canada and Japan, including an issued U.S. patent and pending Canadian and Japanese patents for use in fibromyalgia. The...
08:00 , Feb 2, 2009 |  BC Week In Review  |  Clinical News

CNSBio Pty. Ltd. preclinical data

In rodent models of induced diabetic neuropathy and hyperalgesia, IV leconotide in combination with flupirtine, a potassium channel agonist, reduced pain compared with ziconotide , a calcium channel blocker. Leconotide is a calcium channel blocker...
08:00 , Dec 22, 2008 |  BioCentury  |  Product Development

Fibromyalgia pipeline

Fibromyalgia pipeline Company Product Product description Status Eli Lilly (NYSE:LLY) Cymbalta duloxetine Selective serotonin and norepinephrine reuptake inhibitor (SSNRI) Mkt (A) Pfizer (NYSE:PFE) Lyrica pregabalin GABA receptor agonist Mkt (A) Cypress (NASDAQ:CYPB)/Forest (NYSE:FRX)/Laboratoires Pierre Fabre...
07:00 , Sep 29, 2008 |  BioCentury  |  Product Development

Ophthalmic deals

Ophthalmic deals Date Companies Value [upfront; milestones/royalties] Description Sep 08 Acucela/Otsuka (Tokyo:4768) [$5M; up to $258M] Partner to develop a pair of compounds for ophthalmic indications: Acucela's ACU-4429 for dry age-related macular degeneration (AMD) and...
07:00 , Aug 11, 2008 |  BC Week In Review  |  Company News

Meda, Valeant Pharmaceuticals International deal

Meda will acquire Valeant’s Eastern and Western European business operations for $392 million in cash. Meda said the deal gives it a foothold in Russia, where it plans to introduce its own products, as well...
07:00 , Jun 2, 2008 |  BC Week In Review  |  Company News

Pipex deal

Pipex received an option to license exclusive, worldwide rights to Karl-Georg Schmidt’s IP covering Effirma oral flupirtine for ophthalmic diseases, diabetes and diabetes-related indications. Schmidt, a physician in private practice, holds the patents to use...
07:00 , Apr 28, 2008 |  BC Week In Review  |  Clinical News

Flupirtine: Phase II start

This year, Pipex will begin a double-blind, placebo-controlled, U.S. Phase II trial of oral flupirtine in up to 90 patients for up to 90 days. Pipex Pharmaceuticals Inc. (AMEX:PP), Ann Arbor, Mich.   Product: Flupirtine...